Bailard’s Artiva Biotherapeutics ARTV Stock Holding History

Bailard’s Portfolio ARTV Stock Details ARTV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$201K	Hold	20,700	–	–	﹤0.01%	737
2026 Q1	$133K	Buy	+20,700	New	+$102K	﹤0.01%	715

Other funds holding ARTV

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

Blackstone Inc New York $32.9B AUM 23.66% 1-Year Est. Return

5VM

5AM Venture Management San Francisco, California $288M AUM 313.93% 1-Year Est. Return

VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return

BOCH

Blue Owl Capital Holdings New York $665M AUM 95.48% 1-Year Est. Return

Bailard's ARTV Position: Q2 2026 in Review

Bailard held its Artiva Biotherapeutics (ARTV) position steady in Q2 2026 at 20,700 shares worth $201K. The position accounts for ﹤0.01% of the portfolio, ranked #737.

Bailard first reported a position in ARTV in Q1 2026 and has held it in 2 quarters since. 72 funds tracked by Wall St. Rank hold ARTV as of Q2 2026.

Bailard held 20,700 shares of Artiva Biotherapeutics worth $201K as of Q2 2026.
Bailard left its Artiva Biotherapeutics share count unchanged in Q2 2026.
Artiva Biotherapeutics made up ﹤0.01% of Bailard's portfolio in Q2 2026, its #737 holding.
Bailard first reported a position in Artiva Biotherapeutics in Q1 2026 and has held it in 2 quarters since.
72 funds tracked by Wall St. Rank held Artiva Biotherapeutics as of Q2 2026.

Based on Bailard's 13F filing for Q2 2026, filed 30 Jul 2026.